Giovanna Masci

Milan, 20089, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy.

Baseline Hemostatic Biomarker Assessment Identifies Breast Cancer Patients at High Risk for Venous Thromboembolism During Chemotherapy.

Journal: Cancers

Published: July 14, 2025

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Journal: The oncologist

Published: June 16, 2025

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Real-world patterns of post-progression treatment and outcomes in patients with HR+/HER2- advanced breast cancer treated with CDK4/6 inhibitors.

Journal: The oncologist

Published: June 16, 2025

Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer.

Activated factor XI-antithrombin and thrombin-antithrombin complexes in the prediction of venous thromboembolism and mortality in patients with non-small-cell lung cancer.

Journal: Journal of thrombosis and haemostasis : JTH

Published: October 16, 2024

Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy.

Pre-existing and emerging immune-mediated diseases in patients with breast cancer undergoing cyclin-dependent kinases 4/6 inhibitors and endocrine therapy.

Journal: The oncologist

Published: September 30, 2024

Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients.

Decoding NATALEE and MonarchE eligibility criteria in a real-world cohort of early breast cancer patients.

Journal: The oncologist

Published: September 23, 2024

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial.

Cardioprotection with nebivolol in patients undergoing anthracyclines: a randomized placebo-controlled trial.

Journal: Cardiovascular research

Published: June 19, 2024

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer.

Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer.

Journal: Biomedicines

Published: December 15, 2023

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy.

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy.

Journal: International journal of molecular sciences

Published: December 06, 2023

Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.

Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions.

Journal: Critical reviews in oncology/hematology

Published: November 01, 2023

A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.

A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.

Journal: Cancers

Published: August 14, 2023

Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.

Nebivolol versus placebo in patients undergoing anthracyclines (CONTROL Trial): rationale and study design.

Journal: Journal of cardiovascular medicine (Hagerstown, Md.)

Published: June 07, 2023

Showing 1-12 of 61

Last Updated: 09/26/2026